BioSpace News Archive

Ermium Therapeutics is announcing today the establishment of a scientific advisory board.

The Preeclampsia Foundation announced today the recipients of its 2022 Peter Joseph Pappas Research Grants at the Society for Maternal Fetal Medicine 42nd Annual Pregnancy Meeting.

Shineco, Inc. announced that on January 30, 2022, the Company entered into certain cooperation agreement with Weifang Jianyi Medical Devices Co., Ltd. to jointly manufacture and sell nuclear medicine imaging devices, including PET, PET-CT, and PET-MRI, for comprehensively improving the quality of imaging examination and diagnosis and treatment of specialized hospitals for tumor.

We are excited to announce that our new toxicology facility in Suzhou, China has achieved a key milestone when Jiangsu’s Provincial Department of Science and Technology granted the site an “Experimental Animal Use License” on January 21, 2022, following an on-site inspection and review of recently completed construction.

Crohn’s and Colitis Canada is pleased to announce a $1 million PIONEER Grant from Takeda Canada, which will support the Canadian Inflammatory Bowel Disease Research Consortium.

According to Emergen Research, the global research antibodies market size was USD 3,354.2 million in 2019 and is expected to reach USD 5,325.8 million in 2027 and register a revenue CAGR of 5.9% during the forecast period, 2020-2027.

UBC enters into partnership with Seqster for a best-in-class patient engagement platform to provide real-time, real-world connectivity.

ESSA Pharma Inc. today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2021.

Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022.

Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI) detection methods in certain types of solid tumors.